CG Inbites Reveals 13 Clinical Results of 'Camrelizumab' at ESMO

CG Inbites announced on the 25th that research results on various indications of the immuno-oncology drug "Camrelizumab," for which it holds the rights, will be disclosed at the "European Society for Medical Oncology (ESMO 2023)" to be held in Madrid, Spain, from the 20th to the 24th of next month (local time).

CG Invites CI. [Image provided by CG Invites]

According to CG Inbites' partner, Hansoh Pharmaceutical, major research results on Camrelizumab will be presented at ESMO.

The key research results to be presented include: ▲the first interim analysis results of the phase 3 triple combination clinical trial (DRAGON IV) of Camrelizumab with rivoceranib plus chemotherapy (chemo) for locally advanced resectable gastric or gastroesophageal junction adenocarcinoma (G/GEJ); ▲an update on the phase 2 clinical trial results of neoadjuvant therapy combining Camrelizumab and apatinib for resectable non-small cell lung cancer (NSCLC) patients; ▲results of neoadjuvant therapy combining Camrelizumab and chemotherapy for resectable esophageal squamous cell carcinoma (ESCC) patients; and ▲overall survival (OS) data of the triple combination therapy of Camrelizumab, nab-paclitaxel, and famitinib as first-line treatment for advanced triple-negative breast cancer (TNBC).

In particular, the first interim analysis results of the phase 3 triple combination clinical trial (DRAGON IV) of Camrelizumab with rivoceranib plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma (G/GEJ) will be presented orally in a separate session. Clinical results for the other indications will be presented in poster format.

Previously, Camrelizumab has had research results published for several indications. In the phase 3 clinical trial (CameL study) combining Camrelizumab with carboplatin and pemetrexed as first-line treatment for advanced non-squamous non-small cell lung cancer, published in The Lancet Respiratory Medicine, the median overall survival (mOS) was 27.9 months, representing the longest OS among global immuno-oncology clinical studies for this type of lung cancer at the time of publication.

Additionally, in the ESCORT study for second-line treatment of advanced or metastatic esophageal cancer, the objective response rate (ORR) in the Camrelizumab treatment group reached 20.2%, with an mOS of 8.3 months. This study was recognized for breaking the survival limit phenomenon in esophageal cancer over the past decades and was published in the oncology journal The Lancet Oncology.

A CG Inbites official stated, "Based on the total of 13 Camrelizumab clinical results to be disclosed at ESMO, we will continuously discuss development priorities with Hansoh Pharmaceutical."

This content was produced with the assistance of AI translation services.